BOSTON--(BUSINESS WIRE)--The Harvard Clinical Research Institute (HCRI) announced today that it has begun enrolling patients into the BELT (Blacks and Exacerbations on LABA vs. Tiotropium) Study, the purpose of which is to investigate whether Black patients with asthma are more likely to experience adverse outcomes as a result of long-acting beta-agonist (LABA) therapy. The BELT study was funded by a grant from the Agency for Healthcare Research and Quality (AHRQ). The principal investigator of the study is Dr. Elliot Israel, the Director of Clinical Research in the Pulmonary Division at Brigham and Women’s Hospital in Boston.
